Atrium Health Cabarrus/LCI-Concord

Summary

Atrium Health Cabarrus/LCI-Concord is a medical facility located in Concord, North Carolina. This center is recognized for care of Breast Cancer, Lung Cancer, Breast cancer, Ovarian Cancer, Small Cell Lung Cancer and other specialties. Atrium Health Cabarrus/LCI-Concord is involved with conducting 87 clinical trials across 167 conditions. There are 13 research doctors associated with this hospital, such as Nilanjan Ghosh, Earle Burgess, MD, John H. Heinzerling, and Daniel R. Carrizosa.

Top PIs

Clinical Trials running at Atrium Health Cabarrus/LCI-Concord

Skin Cancer

Laryngeal Cancer

Breast Cancer

Lung Cancer

Oropharyngeal Carcinoma

Small Cell Lung Cancer

Throat Cancer

Cancer

Oropharyngeal Cancer

Lip and Oral Cavity Cancer

Cemiplimab + Surgery

for Advanced Skin Cancer

This phase III trial compares the effect of adding cemiplimab to standard therapy (surgery with or without radiation) versus standard therapy alone in treating patients with stage III/IV squamous cell skin cancer that is able to be removed by surgery (resectable) and that may have come back after a period of improvement (recurrent). The usual treatment for patients with resectable squamous cell skin cancer is the removal of the cancerous tissue (surgery) with or without radiation, which uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Immunotherapy with monoclonal antibodies, such as cemiplimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cemiplimab has been approved for the treatment of skin cancer that has spread or that cannot be removed by surgery, but it has not been approved for the treatment of skin cancer than can be removed by surgery. Adding cemiplimab to the usual treatment of surgery with or without radiation may be more effective in treating patients with stage III/IV resectable squamous cell skin cancer than the usual treatment alone.

Recruiting

2 awards

Phase 3

7 criteria

BMX-001

for Head and Neck Cancer

This phase II trial compares the effectiveness of adding BMX-001 to usual symptom management versus usual symptom management alone for reducing oral mucositis in patients who are receiving chemoradiation for head and neck cancer. Oral mucositis (inflammation and mouth sores) is a common side effect of chemoradiation that can cause pain and difficulty swallowing. Usual management of these side effects typically consists of using mouth rinses and pain medications during treatment and for several weeks after completion of treatment. BMX-001 neutralizes harmful substances in the body, preventing damage to macromolecules such as DNA and minimizes free radical-related toxicity in normal tissues. Adding BMX-001 to usual symptom management may be more effective than usual symptom management alone at reducing oral mucositis in patients receiving chemoradiation for head and neck cancer.

Recruiting

0 awards

Phase 2

7 criteria